New cancer drug shows early promise for Tough-to-Treat stomach and colon cancers
NCT ID NCT04513223
Summary
This early-stage study tested a new drug called SHR-A1811 in 101 patients with advanced stomach or colorectal cancer that had stopped responding to standard treatments. The main goals were to find a safe dose and check for early signs that the drug might help control these cancers. Researchers looked at how patients' bodies handled the drug and whether their tumors shrank or stopped growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, Shanghai, China
Conditions
Explore the condition pages connected to this study.